CoronaryAtlas logo
CoronaryAtlas
Matrix metalloproteinase-1
Pathway / Fibrous-cap degradation & rupture

Matrix metalloproteinase-1

MMP1protein

Matrix metalloproteinase-1 degrades fibrous cap collagen and extracellular matrix, triggering atherosclerotic plaque rupture and thrombus exposure.

Pathway placement
Cascade stepFibrous-cap degradation & rupture
Confidencehigh
RationaleECM proteolysis and fibrous cap degradation; atherosclerotic plaque rupture mediator.
Also acts inVascular inflammation
Druggability
DruggableYes
Known drugs / candidates4
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000196611

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
70
C — confounder / Type-II
80
A — assay feasibility
72
E — evidence strength
31
T1DI (composite)
10
Specificity differential (R−C)-9.8
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Human genetic evidence

0.259
Open Targets association (STEMI)

Literature evidence(3)